Rep. Tom Price and health policy consultant Seema Verma will spearhead Trump Administration efforts to reform the Affordable Care Act as HHS secretary and administrator of CMS, respectively.
President-elect Donald Trump’s choices to lead HHS and the Centers for Medicare and Medicaid Services demonstrate his focus on implementing alternatives to the Affordable Care Act – and not just repealing it.
The Trump transition team announced Nov. 29 that Rep. Tom Price, R-Ga., will be nominated as HHS secretary and a...
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.
Pink Sheet reporter and editors discuss CBER Director Vinay Prasad’s expectation to stay out of routine application decisions, despite the agency’s top-down leadership approach, and the extent of proposed FDA budget cuts.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.
